Anti-epileptogenic Effects of Eslicarbazepine Acetate

Summary

This study aims to assess if eslicarbazepine acetate (ESL) treatment (started within 96 hours after stroke occurrence and continued for 30 days) changes the incidence of unprovoked seizures (USs) within the first 6 months after randomisation as compared to placebo

Timeline

Start

2019-05-29

Primary completion

2023-09-11

Completion

2023-09-11

Drugs

Indications